2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-114761
    Prostaglandin F2α dimethyl amine 67508-09-2 98%
    Prostaglandin F2α dimethyl amine is a Prostaglandin F2α (HY-12956) derivative. Prostaglandin F2α dimethyl amine is an antagonist for Prostaglandin F receptor (FP). Prostaglandin F2α dimethyl amine blocks the cardiovascular responses induced by orexin and Arachidonic acid (HY-109590).
    Prostaglandin F2α dimethyl amine
  • HY-114792
    15-Methylprostaglandin E1 35700-26-6 98%
    15-Methylprostaglandin E1 (15S-15-Methyl-PGE1) exhibits a positiv chronotropic effect, increases the heart rate and levels of nicardipine.
    15-Methylprostaglandin E1
  • HY-114898
    ML404 1826026-00-9 98%
    ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC50=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke.
    ML404
  • HY-114920
    Piprofurol 40680-87-3 98%
    Piprofurol is a calcium channel inhibitor. Piprofurol inhibits the calcium-induced contractions in isolated potassium depolarized preparations of rat aorta in a concentration-dependent manner and relaxes the K+-induced contraction of the dog coronary artery and the rabbit basilar artery. Piprofurol exerts a negative inotropic effect on guinea-pig papillary muscle, with the EC50 of 5 μM.
    Piprofurol
  • HY-114947
    9-deoxy-9-methylene Prostaglandin E2 61263-32-9 98%
    9-deoxy-9-methylene Prostaglandin E2 (9-deoxy-9-methylene PGE2) is a stable, isosteric analog of PGE2. 9-deoxy-9-methylene PGE2 retains the biological profile of PGE2 with fewer side effects. In the rat 9-deoxy-9-methylene PGE2 is equipotent to PGE2 in decreasing blood pressure. It also stimulates the gerbil colon and primate uterus at the same potency as PGE2.
    9-deoxy-9-methylene Prostaglandin E2
  • HY-114952
    SM-32504 185539-34-8 98%
    SM-32504 is an effective ACAT inhibitor that can significantly reduce serum cholesterol levels in mouse models fed with high-fat and high-cholesterol diets. SM-32504 can be used for research on hypercholesterolemia and atherosclerosis.
    SM-32504
  • HY-114953
    BMS-248360 254737-87-6 98%
    BMS-248360 is a potent and orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor, with Kis of 10 nM and 1.9 nM for hAT1 and hETA receptor, respectively. BMS-248360 displays hypertensive effects.
    BMS-248360
  • HY-114961
    15-epi Prostaglandin A1 20897-92-1 98%
    15-epi Prostaglandin A1 (15-epi PGA1) is the 15(R) stereoisomer of PGA1. PGA1 causes renal vasodilation, increased urine sodium excretion, and decreased arterial pressure in hypertensive models.
    15-epi Prostaglandin A1
  • HY-114986
    6-Keto-PGE1 67786-53-2 ≥99.0%
    6-Keto-PGE1 (6-keto-Prostaglandin E1) is a bioactive derivative of PGE1. 6-Keto-PGE1 has hemodynamic and cytoprotective effects in traumatic shock.
    6-Keto-PGE1
  • HY-114990
    EMD 57439 148714-88-9 98%
    EMD 57439 is a selective PDE-III inhibitor. EMD 57439 does not significantly increase c-AMP concentration and has little effect on Ca(50).
    EMD 57439
  • HY-115356
    Eoxin E4 1000852-57-2 98%
    Eoxin E4 (14,15-LTE4) is the metabolite of 14,15-LTC4 and 14,15-LTD4. Eoxin E4 increases vascular permeability of human endothelial cell monolayers with about 10-fold less potency than LTC4, but approximately 100-fold greater potency than histamine.
    Eoxin E4
  • HY-115363
    Curcumenone 100347-96-4
    Curcumenone is a major constituent of the plants of medicinally important genus of Curcuma. Curcumenone, a caraborane type sesquiterpene has been reported to be a vasorelaxant, hepatoprotective and an effective inhibitor of intoxication.
    Curcumenone
  • HY-115382
    Guanoctine hydrochloride 1070-95-7 98%
    Guanoctine hydrochloride exhibits antihypertensive properties.
    Guanoctine hydrochloride
  • HY-115390
    14,15-Dehydro Leukotriene B4 114616-11-4 98%
    14,15-Dehydro Leukotriene B4 (Compound 4) is a LTB4 receptor antagonist. 14,15-Dehydro Leukotriene B4 also has a higher binding affinity for BLT1 with a Ki value of 27 nM and BLT2 with a Ki value of 473 nM. 14,15-Dehydro Leukotriene B4 inhibits LTB4-induced release of lysozymes from rat polymorphonuclear leukoctyes with an IC50 value of 1 µM.
    14,15-Dehydro Leukotriene B4
  • HY-115420
    1-β-D-Glucosylsphingadienine (d18:2 (4E8E)) 114200-59-8 98%
    1-β-D-Glucosylsphingadienine (d18:2 (4E8E)) is a glucosylsphingosine, which are deacetylated lysolipid derivatives of glucosylcerebrosides.
    1-β-D-Glucosylsphingadienine (d18:2 (4E8E))
  • HY-115477
    Brilaroxazine hydrochloride 1708960-04-6 98%
    Brilaroxazine (RP5063) hydrochloride is a modulator of serotonin receptors, exhibiting potential therapeutic activity in the treatment of pulmonary arterial hypertension (PAH). Brilaroxazine hydrochloride has been shown to limit functional and structural changes associated with PAH, leading to significant improvements in pulmonary hemodynamics and right ventricular hypertrophy. Brilaroxazine hydrochloride also enhances oxygen saturation levels and alleviates elevated pulmonary arterial pressures when used as an adjunct to standard PAH therapies.
    Brilaroxazine hydrochloride
  • HY-115494
    Neladenoson dalanate hydrochloride 1239235-25-6 98%
    Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) hydrochloride is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate hydrochloride has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases.
    Neladenoson dalanate hydrochloride
  • HY-115911
    GPVI antagonist 2 880399-00-8 98%
    GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent.
    GPVI antagonist 2
  • HY-115912
    GPVI antagonist 3 901654-94-2 98%
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent.
    GPVI antagonist 3
  • HY-116042
    FSCPX 156547-56-7 99.72%
    FSCPX is a potent and selective irreversible antagonist of A1 adenosine receptor (A1AR), with low nanomolar potency for binding to the A1AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial adenosine level in the guinea pig atrium.
    FSCPX
Cat. No. Product Name / Synonyms Application Reactivity